Literature DB >> 16816838

B cells move to centre stage: novel opportunities for autoimmune disease treatment.

Jeffrey L Browning1.   

Abstract

The B-cell arm of the immune system has long been appreciated for its crucial role in pathogen resistance, but in the study of many autoimmune diseases, T cells have dominated the limelight for decades. However, the development of the B-cell-depleting antibody rituximab as a lymphoma therapy has provided a tool to probe the contribution made by B cells in several immune disorders. Recently, the success of B-cell depletion with rituximab in the treatment of rheumatoid arthritis has stimulated investigation of its effects in several other immune disorders, and considerable interest in the potential of drugs that can modulate B-cell function for the treatment of such diseases in general. This article discusses the role of B cells in a range of autoimmune disorders, including rheumatoid arthritis and systemic lupus erythematosus, and analyses approaches to therapeutic B-cell manipulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816838     DOI: 10.1038/nrd2085

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  104 in total

Review 1.  Fibrosis: ultimate and proximate causes.

Authors:  Victor J Thannickal; Yong Zhou; Amit Gaggar; Steven R Duncan
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

2.  Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.

Authors:  Mathangi Srinivasan; Ryan Flynn; Andrew Price; Ann Ranger; Jeffrey L Browning; Patricia A Taylor; Jerome Ritz; Joseph H Antin; William J Murphy; Leo Luznik; Mark J Shlomchik; Angela Panoskaltsis-Mortari; Bruce R Blazar
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

3.  B-cell-targeted therapy for the fibrotic complications of systemic sclerosis.

Authors:  Robert Woodrick; John Varga
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

4.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

5.  A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sjögren's syndrome and systemic lupus erythematosus.

Authors:  K Szabó; G Papp; A Szántó; T Tarr; M Zeher
Journal:  Clin Exp Immunol       Date:  2015-10-21       Impact factor: 4.330

Review 6.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

Review 7.  Activation-induced cytidine deaminase and aberrant germinal center selection in the development of humoral autoimmunities.

Authors:  Ahmad Zaheen; Alberto Martin
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 8.  B-cell inhibitors as therapy for rheumatoid arthritis: an update.

Authors:  Jennifer Kwan-Morley; Daniel Albert
Journal:  Curr Rheumatol Rep       Date:  2007-10       Impact factor: 4.592

9.  Risk factor for ischemic-type biliary lesion after ABO-incompatible living donor liver transplantation.

Authors:  Jun Bae Bang; Bong-Wan Kim; Young Bae Kim; Hee-Jung Wang; Hyun Yeong Lee; Joohyun Sim; Taegyu Kim; Kyeong Lok Lee; Xu-Guang Hu; Wei Mao
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 10.  Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.

Authors:  M C Levesque
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.